Research News

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian…

Read on

Webinar Highlights Research News from ASCO

On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research  news that was presented at 2014’s medical meetings…

Read on

Report from the 2014 American Society of Clinical Oncology Annual Meeting

Promising new combination treatments for ovarian cancer Dr…

Read on

2014 ASCO Research Round-Up

Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought provoking studies on ovarian cancer…

Read on

ASCO News: Two New Drugs Show Promise for Recurrent Ovarian Cancer

(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine…

Read on

FDA Seeking Comments on Olaparib by June 11

The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval…

Read on

Breastfeeding, Birth Control Pills May Reduce Ovarian Cancer Risk Among Women with BRCA Gene Mutations

(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive…

Read on

OCRF Research Shows How Ovarian Tumors Elude Immune System

(May 6, 2014) Tumors use numerous mechanisms to escape detection and killing by the immune system…

Read on

Imaging Predicts Response in Ovarian Cancer

(April 30, 2014) A positive pretreatment imaging test more than doubled the likelihood of disease control in platinum-resistant advanced ovarian cancer treated with the folate receptor-targeted drug vintafolide (trade name Vynfinit), results of a…

Read on

SGO and AACR Research Round-Up

With two marquee scientific conferences, the Society for Gynecologic Oncology (SGO) and the American Association for Cancer Research (AACR), occurring back-to-back, the past few weeks have seen an explosion in ovarian cancer research news…

Read on

News from AACR: Irregular Menses Linked to High Risk of Ovarian Cancer

(April 15, 2014) Prolonged (>35 days), infrequent, or anovulatory menstrual cycles was associated with as much as a two-fold increase in ovarian cancer and more than a three-fold increase in the risk of fatal ovarian cancer, according to a…

Read on

Physical Activity Associated with Lower Risk of Ovarian Cancer Mortality

(April 8, 2014) A team of researchers have found that vigorous physical activity prior to ovarian cancer diagnosis was associated with a lower risk of ovarian cancer mortality.  The findings were published in Gynecologic Oncology…

Read on
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]